J Mateo
Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
Lorente D, Sartor O, Su Z, Shen L, Bahl A, Ferraldeschi R, Bianchini D, Zafeiriou Z, Templeton A, Mateo J, de Bono J. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol 2014
23.12.2014Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
23.12.2014Ann Oncol 2014
Lorente D, Sartor O, Su Z, Shen L, Bahl A, Ferraldeschi R, Bianchini D, Zafeiriou Z, Templeton Arnoud, Mateo J, de Bono J S
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
Lorente D, de Bono J, Gillessen Sommer S, Dearnaley D, Parker C, Tunariu N, Zafeirou Z, Altavilla A, Mateo J, Perez R, Pezaro C, Ferraldeschi R, Omlin A, Attard G. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer 2014
14.10.2014Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
14.10.2014Br J Cancer 2014
Lorente D, de Bono J, Gillessen Sommer Silke, Dearnaley D, Parker C, Tunariu N, Zafeirou Z, Altavilla A, Mateo J, Perez R, Pezaro C, Ferraldeschi R, Omlin Aurelius, Attard G